An example of drug repurposing in the oncology field worth mentioning is Imatinib, which targets the BCR-ABL fusion protein in chronic myeloid leukemia (CML) but additionally inhibits v-kit oncogene homolog (KIT) and platelet-derived growth factor receptors (PDGFRs), which are gastrointestinal stromal tumor (GIST) oncogenes [21]. This evidence concerns the gene BCR and gastrointestinal stromal tumor.